Business
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
CARLSBAD, Calif., Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing
About this update from Tyra Biosciences, Inc.
[{"type":"text","content":"CARLSBAD, Calif., Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG) 2023 annual meetings. \nASBMR is taking place October 13-16, 2023, in Vancouver, BC, Canada and ASHG is taking place November 1-5, 2023, in Washington, DC. \nASBMR presentation details:\nTitle: \"TYRA-300 Demonstrates Significant Increases in Growth and Bone Length in a Mouse Model of FGFR3-Related Skeletal Dysplasia\"Presentation Number: 1077Session: Oral Presentations: Skeletal Development and DiseasePresentation Date/Time: Sunday, October 15, 2023, 10:00 AMTYRA Presenter: Ronald Swanson, Ph.D., Chief Scientific Officer\nASHG presentation details:\nTitle: \"TYRA-300 Demonstrates Significant Increases in Growth and Bone Length in a Mouse Model of FGFR3-Related Skeletal Dysplasia\"Session: Oral Presentations: Precision prescription: The therapeutic potential of ASOs and small molecules for genetic disordersPresentation Date/Time: Friday, November 3, 2023, 12:00 PMTYRA Presenter: Jacqueline H. Starrett, PhD, Associate Director, In Vivo Pharmacology\nMore information on the annual meetings can be found below:\nASBMR 2023 Annual Meeting - American Society for Bone and Mineral ResearchASHG 2023 Scientific Program and Schedule of Events - ASHGThe presentation materials will be made available via the For Investors page on the Investor section of the TYRA website. \nAbout TYRA-300\nTYRA-300 is the Company's lead precision medicine program stemming from its in-house SNÅP platform. TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias including achondroplasia. TYRA-300 is being evaluated in a multi-center, open label Phase 1/2 clinical study, SURF301 (Study in Untreated and Resistant FGFR3+ Advanced Solid Tumors). SURF301 (NCT05544552) was designed to determine the optimal and maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D) of TYRA-300, as well as to evaluate the preli...